基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

劳动节休市 04-30 16:08:13

9.300

-0.190

-2.00%

最高9.530	最低9.090	成交量910.10万
今开9.500	昨收9.490	日振幅4.64%
总市值148.80亿	流通市值148.80亿	总股本16.00亿
成交额8,418万	换手率0.57%	流通股本16.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":9.3,"timestamp":1777536493006,"preClose":9.49,"halted":0,"volume":9100973,"delay":0,"changeRate":-0.02002107481559531,"floatShares":1600000000,"shares":1600000000,"eps":-0.314752,"marketStatus":"劳动节休市","change":-0.19,"latestTime":"04-30 16:08:13","open":9.5,"high":9.53,"low":9.09,"amount":84184610,"amplitude":0.046365,"askPrice":9.3,"askSize":8000,"bidPrice":9.29,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":9.49,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.8891340443734704,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"1177023630","title":"异动解读 | 基石药业-B盘中大跌5.17%，配股稀释与业绩亏损双重压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1177023630","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177023630?lang=zh_cn&edition=full","pubTime":"2026-04-28 15:27","pubTimestamp":1777361238,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大跌5.17%，引起了市场的广泛关注。消息面上，公司近期完成了大规模股份发行，根据配售协议以每股8.97港元的价格配发了约1.18亿股新股，占配发前已发行股本约7.99%，同时通过受限制股份奖励计划再发行了600万股。这使得公司股本在短期内显著扩大，股权稀释压力明显，且配售价较市价存在折价，导致市场抛压持续释放。此外，公司最新披露的年度业绩显示，其收入同比下滑33.8%至约2.70亿元人民币，年内亏损则从约0.91亿元大幅扩大至4.37亿元，研发投入也有所增加，经营压力上升。配股带来的稀释效应与基本面承压的双重因素叠加，共同导致了股价的下跌。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159919357","title":"基石药业-B（02616）2025年业绩速览：收入下滑33.8%，差异化研发管线稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1159919357","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159919357?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:06","pubTimestamp":1777284381,"startTime":"0","endTime":"0","summary":"基石药业-B于2025年年度实现收入约2.70亿元人民币，较上一年度的4.07亿元减少33.8%，主要受商业化与授权收入下降影响。同期收入成本为2.18亿元，毛利约0.51亿元。研发投入增至3.12亿元，较此前1.35亿元大幅提升，主要因关键临床试验和新药项目加速推进。销售及市场推广开支约0.83亿元，行政开支约0.89亿元。整体来看，年内亏损从上一年度约0.91亿元扩大至4.37亿元，经营压力显著上升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B（02616）2025年业绩速览：收入下滑33.8%，差异化研发管线稳步推进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145260957","title":"异动解读 | 基石药业-B盘中大跌5.90%，大额配股稀释效应持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1145260957","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145260957?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:04","pubTimestamp":1776996250,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大跌5.90%，引起了市场的广泛关注。消息面上，公司此前根据配售协议以每股8.97港元的价格配发及发行1.18亿股新股，占配发前已发行股本约7.99%，总筹资约10.53亿港元。此外，公司于4月23日通过受限制股份奖励计划再发行600万股新股。短期内大规模新股发行导致股本从约14.76亿股扩大至约16亿股，股权稀释压力显著，叠加配售价较当前股价存在折价，市场抛压持续释放。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181091599","title":"基石药业-B：4月23日发行600万股，占已发行股本约0.376%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181091599","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181091599?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:36","pubTimestamp":1776947762,"startTime":"0","endTime":"0","summary":"基石药业-B（02616）于2026年4月23日发布公告，披露公司通过其受限制股份奖励计划发行6,000,000股新股份，约占发行前已发行股本的0.376%。每股发行价为USD0.0001。此次发行完成后，公司已发行股本增至1,600,239,783股。\n公司在公告中确认，相关股份发行已获得董事会正式授权并遵守香港联合交易所有限公司证券上市规则及其他适用法律法规。公告由公司董事李伟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B：4月23日发行600万股，占已发行股本约0.376%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160291683","title":"异动解读 | 基石药业-B发行1.18亿股新股，盘中大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160291683","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160291683?lang=zh_cn&edition=full","pubTime":"2026-04-23 11:24","pubTimestamp":1776914647,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大跌5.02%，引起了市场的广泛关注。消息面上，基石药业-B发布公告，根据2026年4月14日的配售协议，于2026年4月22日以一般授权配发及发行1.18亿股新股份。此次发行新股可能导致股权稀释，从而对股价产生压力。市场分析人士指出，新股发行通常会增加流通股数量，可能影响每股收益，投资者因此抛售股票，导致股价下跌。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629425042","title":"基石药业-B(02616)根据配售协议发行1.18亿股新股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629425042","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629425042?lang=zh_cn&edition=full","pubTime":"2026-04-22 21:43","pubTimestamp":1776865439,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，根据2026年4月14日的配售协议于2026年4月22日以一般授权配发及发行1.18亿股新股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192948925","title":"基石药业-B：4月22日配发1.18亿新股，涉资约10.58亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192948925","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192948925?lang=zh_cn&edition=full","pubTime":"2026-04-22 21:36","pubTimestamp":1776865011,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年4月22日发布公告，披露其已发行股本出现变动。公告称，公司在2026年4月1日至4月22日期间，因多次行使雇员持股计划授予的期权发行普通股共计221,061股，发行价格区间介乎每股港币0.39港元至4.619港元。此外，公司于4月22日根据4月14日签订的配售协议，以一般授权配发及发行118,000,000股新股，约占配发前已发行股本的7.99%，发行价格为每股8.97港元，涉资约10.58亿港元。本次发行完成后，公司已发行股本由1,476,018,722股增至1,594,239,783股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"基石药业-B：4月22日配发1.18亿新股，涉资约10.58亿港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115060099","title":"异动解读 | ASCO年会公布关键临床数据叠加机构增持，基石药业-B盘中大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115060099","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115060099?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:34","pubTimestamp":1776821687,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大幅上涨5.10%，引起市场关注。披露内容将涵盖CS2009在非小细胞肺癌一线及后线治疗中的I/II期临床试验数据，以及在晚期实体瘤患者中的I期临床延长随访结果。根据香港联交所权益披露文件，高瓴资本旗下HHLR于4月15日斥资约2.35亿港元增持公司2620万股，持股比例升至6.01%。同日，摩根士丹利也增持了约795.92万股，涉资约7541.72万港元。两家知名投资机构的同步增持，显著增强了市场对该公司未来发展的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629067754","title":"基石药业-B早盘高开近5% 将于2026年ASCO年会公布CS2009多项临床关键进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629067754","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629067754?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:29","pubTimestamp":1776821340,"startTime":"0","endTime":"0","summary":"　　基石药业-B早盘高开近5%，截至发稿，股价上涨4.99%，现报10.3港元，成交额321.36万港元。　　4月22日，基石药业-B发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的多项临床关键进展，将在今年美国临床肿瘤学会年会通过两份壁报正式发布，披露内容将涵盖CS2009在非小细胞肺癌伫列中的I/II期临床试验数据 ，以及在晚期实体瘤患者中的I期临床延长随访结果。　　公告称，CS2009全球多中心I/II期临床试验正在澳大利亚和中国同步迅速推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-22/doc-inhvitah5636524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629061051","title":"基石药业-B(02616)将在美国临床肿瘤学会年会公布CS2009的多项临床关键进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629061051","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629061051?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:07","pubTimestamp":1776816445,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的多项临床关键进展，将在今年美国临床肿瘤学会年会通过两份壁报正式发布，披露内容将涵盖CS2009在非小细胞肺癌伫列中的I/II期临床试验数据 ，以及在晚期实体瘤患者中的I期临床延长随访结果。更加成熟的安全性与PK/PD数据: 基石药业将于ASCO公布临床I期更大人群的延长随访数据，全面呈现CS2009的安全性、耐受性、药代动力学/药效动力学特征。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629367990","title":"HHLR Advisors, Ltd.增持基石药业-B(02616)2620万股 每股作价8.97港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629367990","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629367990?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:50","pubTimestamp":1776772235,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，4月15日，HHLR Advisors, Ltd.增持基石药业-B(02616)2620万股，每股作价8.97港元，总金额约为2.35亿港元。增持后最新持股数目为8866.45万股，持股比例为6.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","EWH","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628794281","title":"基石药业-B(02616)携CS5007(EGFR/HER3)等三款全新/差异化ADC临床前研究成果亮相AACR年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2628794281","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628794281?lang=zh_cn&edition=full","pubTime":"2026-04-20 08:04","pubTimestamp":1776643475,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布，公司在2026年4月17日至22日召开的美国癌症研究协会年会上展出包括CS5007、CS5006及CS5008在内三项自主研发管线的临床前最新研究成果。CS5007是一种双特异性ADC,由抗EGFR/HER3人源IgG1抗体、基石药业专有的亲水性CSL20连接子，以及临床验证的拓扑异构酶I抑制剂Exatecan组成。此外，CS5008抗体产量高、ADC稳定性强、成药性良好。基石药业计划于2026年下半年正式启动CS5008的IND申请工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","ADC","BK4231","BK1161","BK4080","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101991349","title":"异动解读 | 基石药业-B盘中大涨5.05%，因配售股份筹资10.53亿港元用于研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1101991349","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101991349?lang=zh_cn&edition=full","pubTime":"2026-04-16 10:17","pubTimestamp":1776305854,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大涨5.05%，引起了市场的广泛关注。消息面上，基石药业-B发布公告，公司已与配售代理订立配售协议，以每股8.97港元的价格，向不少于六名承配人配售合共1.18亿股股份。假设所有配售股份获悉数认购，配售所得款项净额估计约为10.53亿港元。此举被市场视为对公司未来研发能力和增长潜力的积极信号，从而推动了股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627607257","title":"港股异动 | 基石药业-B(02616)涨超4% 拟合共配售1.18亿股份净筹10.53亿港元 进一步研发“管线”2.0资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2627607257","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627607257?lang=zh_cn&edition=full","pubTime":"2026-04-16 10:00","pubTimestamp":1776304855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨超4%，截至发稿，涨4.44%，报10.34港元，成交额3018.58万港元。消息面上，基石药业-B发布公告，于2026年4月14日，本公司与配售代理订立配售协议，本公司已有条件同意透过配售代理，以每股配售股份8.97港元的价格，向不少于六名承配人配售合共1.18亿股配售股份。假设所有1.18亿股配售股份获悉数认购，于配售完成后，配售所得款项总额将为10.58亿港元，配售所得款项净额估计为10.53亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","VXUS","BK1161","BK1574","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627342004","title":"基石药业-B(02616)拟配售合共1.18亿股配售股份 净筹约10.53亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627342004","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627342004?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:28","pubTimestamp":1776209318,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，于2026年4月14日，本公司与配售代理订立配售协议，本公司已有条件同意透过配售代理，以每股配售股份8.97港元的价格，向不少于六名承配人配售合共1.18亿股配售股份。配售股份将根据一般授权配发及发行，且无需取得任何股东批准。假设所有1.18亿股配售股份获悉数认购，于配售完成后，配售所得款项总额将为10.58亿港元，配售所得款项净额估计为10.53亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166825585","title":"异动解读 | 基石药业-B(02616)盘中大涨6.73%，CS2009临床数据积极叠加券商大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1166825585","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166825585?lang=zh_cn&edition=full","pubTime":"2026-04-10 13:56","pubTimestamp":1775800604,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大涨6.73%，引起了市场的广泛关注。消息面上，公司上月底公布，其核心产品CS2009单药针对肺癌的I/II期初步疗效数据表现积极。公司计划于2026年底前启动CS2009的首批III期全球多中心临床试验，重点布局非小细胞肺癌、结直肠癌、小细胞肺癌等适应症，这为未来的产品上市和商业化前景注入了强心剂。此外，招商证券国际发布最新研报，大幅上调基石药业目标价131.5%至16.9港元，并维持“增持”评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626169563","title":"港股异动 | 基石药业-B(02616)午后涨超6% 机构调高CS2009资产估值 大幅上调公司目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2626169563","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626169563?lang=zh_cn&edition=full","pubTime":"2026-04-10 13:51","pubTimestamp":1775800302,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B午后涨超6%，截至发稿，涨6.73%，报10.15港元，成交额1.2亿港元。招商证券国际发布研报称，上调基石药业目标价131.5%，从7.3港元大升至16.9港元，维持“增持”评级。该行提高对CS2009的资产估值，虽然该资产在未来临床开发存在不确定性，但该行认为公司管理层研发思路明确，战略清晰，也存在和海外大型药业开展深度合作的可能性。CS2009三抗有望突出重围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184074392","title":"基石药业-B公布3月股份变动月报表，新增发行3,349股","url":"https://stock-news.laohu8.com/highlight/detail?id=1184074392","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184074392?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:02","pubTimestamp":1775732527,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年4月9日发布截至2026年3月31日的股份变动月报表。公告显示，本月公司注册股本仍保持2,000,000,000股的水平，每股面值为USD 0.0001，注册股本总额USD 200,000，与上月无异动。根据月报，本月末公司已发行股份由上月的1,476,015,373股增至1,476,018,722股，较上月增加3,349股。2019年首次公开发售后员工持股计划于当月行权3,349股，募集资金总额为HKD 6,067.35。公告同时说明，本月内未发生股份回购或注销事宜。截至3月末，公司确认遵守香港联交所《上市规则》及相关法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625471449","title":"基石药业-B(02616.HK)遭GIC Private Limited减持252万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625471449","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625471449?lang=zh_cn&edition=full","pubTime":"2026-04-08 22:07","pubTimestamp":1775657222,"startTime":"0","endTime":"0","summary":"格隆汇4月8日丨根据联交所最新权益披露资料显示，2026年4月2日，基石药业-B(02616.HK)遭GIC Private Limited在场内以每股均价9.2282港元减持252万股，涉资约2325.51万港元。\r\n\r\n　　减持后，GIC Private Limited最新持股数目为8716.75万股，持股比例由6.08%下降至5.91%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/08/20260408991586.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/08/20260408991586.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260408/32132120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02616","BK1574","BK1161","BK4104","GIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625996649","title":"招商证券国际：大升基石药业(02616)目标价至16.9港元 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2625996649","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625996649?lang=zh_cn&edition=full","pubTime":"2026-04-08 10:46","pubTimestamp":1775616388,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券国际发布研报称，上调基石药业(02616)目标价131.5%，从7.3港元大升至16.9港元，维持“增持”评级。该行提高对PD-1/VEGF/CTLA-4 TsAb (CS2009)的资产估值，虽然该资产在未来临床开发存在不确定性，但该行认为公司管理层研发思路明确，战略清晰，也存在和海外大型药业开展深度合作的可能性。CS2009三抗有望突出重围。市场基于CS2009优异早期数据，正在重新定价并对BD开始预期。该行组织基石药业业绩后NDR，管理阶层对三抗分子Ph2剂量扩展与未来Ph3 MRCT充满信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","06099","EWH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.07},{"period":"1month","weight":0.069},{"period":"3month","weight":0.7318},{"period":"6month","weight":0.4856},{"period":"1year","weight":2.2979},{"period":"ytd","weight":0.7647}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.031371},{"month":5,"riseRate":0.5,"avgChangeRate":0.100514},{"month":6,"riseRate":0.714286,"avgChangeRate":0.09443},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05639},{"month":8,"riseRate":0.428571,"avgChangeRate":0.079119},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.071005},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}